Search clinical trials for: SHR1459 ；YY-20394

Total 50 results

Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Relapsed or Refractory Peripheral T-Cell Lymphoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

PTCL
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Indolent B-cell Lymphoma
Ruijin Hospital
Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

Real World Study of Linperlisib for Lymphoma Treatment (MA-LYM-RWS-001)

Focus on the Lymphoma Including B/T-cell Lymphoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

Effectiveness，Safety，Thymic Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Lymphoma, Follicular

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Peripheral T/NK Cell Lymphoma (R/R PTCL)

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

China
Reistone Biopharma Company Limited

Active, not recruiting

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
Reistone Biopharma Company Limited

Completed

An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

Neuromyelitis Optica Spectrum Disorders

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers

Healthy Volunteers

China
Yuyu Pharma, Inc.

Completed

A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes

Diabetes

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers

Healthy Adult Subjects

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Diffuse Large B Cell Lymphoma
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

Mature B Cell Neoplasms

China
University of Copenhagen
EC-FP6 (contract number: LHM-CT-2003-503041); Aditech Pharma AB

Completed

The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.

Obesity
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects

Healthy Adult Subjects

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in Healthy Participants

Type 2 Diabetes

China
University of Copenhagen
Aditech Pharma AB

Completed

The Role of Peptide YY (PYY)in Inhibiting Food Intake.

Obesity
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight and Obesity

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

China
Gila Therapeutics, Inc.

Completed

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

Feeding and Eating Disorders

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR1258 in Patients With Biliary Tract Cancer

Biliary Tract Cancer
XRad Therapeutics Inc

Completed

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

Metastasis | Recurrent Cancer | Locally Advanced Solid Tumor

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Beijing Tongren Hospital

Recruiting

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

T-lymphoblastic Lymphoma | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Hengrui Therapeutics, Inc.

Unknown

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Breast Cancer | Gastric Cancer | NSCLC | Solid Tumors

United States
Yuyu Pharma, Inc.

Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) (ADHD)

Mental Disorders

Korea, Republic of
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China
Yuyu Pharma, Inc.

Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD (yuyu)

Mental Disorders

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma

United States
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
Jiangsu HengRui Medicine Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Completed

A Phase I Study of SHR1459 in Healthy Subjects

Health, Subjective

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

B-cell Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459

China
University of Sao Paulo General Hospital

Recruiting

L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP

Type 2 Diabetes Mellitus in Obese | Severe Obesity

Brazil
Yuyu Pharma, Inc.

Completed

Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

Benign Prostatic Hyperplasia

Korea, Republic of
First Hospital of China Medical University

Not yet recruiting

Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis

Sporotrichosis
Tibotec Pharmaceuticals, Ireland

Withdrawn

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

HIV Infections

Netherlands
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
Guangdong Association of Clinical Trials
Chinese Thoracic Oncology Group

Recruiting

Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)

Carcinoma, Non-Small-Cell Lung

China
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma

United States

Search clinical trials for: SHR1459 ；YY-20394

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations